ETOPOSIDE

作品数：88被引量：105H指数：5
导出分析报告
相关领域：医药卫生更多>>
相关作者：李捷亓荣华孙广涛魏本尊田伟更多>>
相关机构：吉林大学中国医科大学国家海洋局第三海洋研究所浙江大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家高技术研究发展计划广东省科研条件建设项目福建省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Comparison of irinotecan/carboplatin versus etoposide/carboplatin for extended disease small cell lung cancer(ED-SCLC):A systematic review and meta-analysis of randomized controlled trials
《Malignancy Spectrum》2024年第4期300-311,共12页Zeeshan Afzal Sara Hira Xia Song Na Wang 
Background:Platinum-based chemotherapy in addition to the nonplatinum agent etoposide is the standard of care for extensive-stage small cell lung cancer(ES-SCLC).However,the front-line chemotherapy regimen is not know...
关键词：CARBOPLATIN ED-SCLC ETOPOSIDE IRINOTECAN small cell lung cancer 
Effects of triggers of senescence and senolysis in murine pancreatic cancer cells
《Hepatobiliary & Pancreatic Diseases International》2024年第6期628-637,共10页Denis Revskij Aline Woitas Bianca Kölle Camilla Umstätter Dietmar Zechner Faiz M Khan Georg Fuellen Robert Jaster 
supported by a grant from the Bundesministerium fur Bildung und Forschung(01ZX1903A).
Background:The combination of senescence triggers with senolytic drugs is considered a promising new approach to cancer therapy.Here,we studied the efficacy of the genotoxic agent etoposide(Eto)and irradiation in indu...
关键词：Pancreatic cancer Panc02 cells ETOPOSIDE IRRADIATION Navitoclax 
Successful management of infection and macrophage activation syndrome patient using low-dose etoposide:A case report
《World Journal of Radiology》2024年第10期579-585,共7页Shu-Pei Gao Xiao-Fang Luo Mohammadreza Kosari Wen-Juan Li Liu Yang Wei Tu Ji-Xin Zhong 
Supported by Hubei Provincial Natural Science Foundation of China,No.2023AFB771;National Natural Science Foundation of China,No.82270903 and No.81974254.
BACKGROUND Macrophage activation syndrome(MAS),a sub-type of hemophagocytic lymphohistiocytosis(HLH)secondary to autoimmune rheumatic diseases,is a critical and potentially fatal condition characterized by an excessiv...
关键词：Macrophage activation syndrome Hemophagocytic lymphohistiocytosis INFECTION Systemic lupus erythematosus ETOPOSIDE Case report 
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/Ⅱ trial
《Signal Transduction and Targeted Therapy》2024年第10期4700-4707,共8页Yaxiong Zhang Yan Huang Yunpeng Yang Yuanyuan Zhao Ting Zhou Gang Chen Shen Zhao Huaqiang Zhou Yuxiang Ma Shaodong Hong Hongyun Zhao Li Zhang Wenfeng Fang 
Chinese National Natural Science Foundation Project(Grant No.82173101,82373262,82241232,82272789,82102872,82102864);Guangzhou Basic and Applied Basic Research Foundation(2024A04J4082).
There is still room for improvement in first-line treatment of advanced small cell lung cancer(SCLC).This trial firstly investigated efficacy and safety of antiangiogenic therapy(surufatinib)(200 mg,qd,po)plus anti-PD...
关键词：CISPLATIN patients ETOPOSIDE 
Anlotinib in combination with Envolizumab plus Etoposide for the treatment of EX-SCLC:a case report
《Clinical Research Communications》2024年第1期29-33,共5页Hong-Lei Guo Hong Wang Yan-Qi Song Xin-Long Song Ai-Di Wang Bao-Shan Liu 
Background:Small cell lung cancer(SCLC)is an aggressive malignant tumor with strong immunosuppressive effects,characterized by rapid doubling time and poor prognosis.Currently,effective therapeutic options are urgentl...
关键词：Extensive-stage Small Cell Lung Cancer ANTI-ANGIOGENESIS PD-1 inhibitors Combined treatment case report 
BET inhibitors enhance the anti-cancer effect of etoposide by suppressing the MRN-ATM axis in the DNA damage response
《Genes & Diseases》2024年第1期19-22,共4页Zhenhai Li Wenchao Xu Feng Chen Jun Zhang Wei-Guo Zhu 
supported by the National Key R&D Program of China(No.2017YFA0503900);the National Natural Science Foundation of China(No.32090033,81720108027,81530074,82103275,82002986);the Science and Technology Program of Guangdong Province in China(No.2017B030301016);China Postdoctoral Science Foundation(No.2019M663092);Basic and Applied Basic Research Foundation of Guangdong Province(No.2019A1515110039,2019A1515110041,2021A1515011126);Shenzhen Municipal Commission of Science and Technology Innovation(China)(No.JCYJ20170818092450901,JCYJ20200109114214463).
Etoposide is widely used for cancer chemotherapy in the clinic.However,long-term etoposide treatment can lead to adverse effects or drug resistance.To improve the situation,we evaluated the therapeutic efficiency of e...
关键词：ETOPOSIDE DAMAGE cancer 
Protein-based nanocarriers for efficient Etoposide delivery and cancer therapy被引量：1
《Nano Research》2023年第8期11216-11220,共5页Bo Wang Xiaoxiong Xu Bo Li Zheng Wei Shuang Lu Jingjing Li Kai Liu Hongjie Zhang Fan Wang Yang Yang 
supported by the National Key R&D Program of China(Nos.2020YFA0712102,2018YFA0902600,2021YFF0701800,2020YFA0211100);the National Natural Science Foundation of China(Nos.52222214,22020102003,22125701,21907088,51922077,51872205);the Youth Innovation Promotion Association of CAS(No.2020228);Natural Science Foundation of Jilin Province(No.20210101366JC);the Foundation of National Facility for Translational Medicine(Shanghai)(No.TMSK-2020-012);All animal experiments were conducted in compliance with the Animal Management Rules of the Ministry of Health of the People’s Republic of China and with the approval of the Institutional Animal Care and Use Committee of the Animal Experiment Center of Peking University(No.LA2019313).
Etoposide,a DNA damage-inducing agent,is widely used for malignant tumors.However,insufficient solubility,poor bioavailability and adverse events limited the treatment outcomes and prognosis.To address this,we here de...
关键词：ETOPOSIDE NANOCARRIER SOLUBILITY cellular internalization malignant tumors 
Synthesis, SAR, and in Silico ADME Screening Studies of Some 9-Amino-3-Phenylacridone Derivatives as Topoisomerase II Inhibitors
《Open Journal of Medicinal Chemistry》2023年第2期15-34,共20页Abiodun S. Oyedele Toluwase H. Fatoki Esha Dalvie Neil Osheroff Cosmas O. Okoro 
Cancer is a leading cause of death globally, claiming about 9.6 million lives and approximately 420 million new cases of cancer will be diagnosed in the world by the year 2025. The aim of this study was to synthesize ...
关键词：CANCERS 9-Aminoacridone ANTICANCER Topoisomerase II PHARMACOKINETICS Molecular Docking ETOPOSIDE 
Etoposide,dexamethasone,and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma:A randomized phase III study被引量：3
《The Innovation》2023年第3期70-78,共9页Huijuan Zhong Shu Cheng Xi Zhang Bing Xu Jiayi Chen Xufeng Jiang Jie Xiong Yu Hu Guohui Cui Juying Wei Wenbin Qian Xiaobing Huang Ming Hou Feng Yan Xin Wang Yongping Song Jianda Hu Yuanhua Liu Xuejun Ma Fei Li Chongyang Wu Junmin Chen Li Yu Ou Bai Jingyan Xu Zunmin Zhu Li Liu Xin Zhou Li Huang Yin Tong Ting Niu Depei Wu Hao Zhang Chaofu Wang Binshen Ouyang Hongmei Yi Qi Song Gang Cai Biao Li Jia Liu Zhifeng Li Rong Xiao Luqun Wang Yujie Jiang Yanyan Liu Xiaoyun Zheng Pengpeng Xu Hengye Huang Li Wang Saijuan Chen Weili Zhao 
supported by the Union for China Lymphoma Investigators,and funded by the Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine(DLY201601);the National Key R&D Program of China(2022YFC 2502600);the National Natural Science Foundation of China(82130004,81830007,82070204,and 81670176);Chang Jiang Scholars Program,Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support(20152206 and 20152208);the Clinical Research Plan of Shanghai Hospital Development Center(SHDC2020CR1032B);the Collaborative Innovation Center of Systems Biomedicine,and the Samuel Waxman Cancer Research Foundation.
Methotrexate,etoposide,dexamethasone,and pegaspargase(MESA)with sandwiched radiotherapy is known to be effective for early-stage extranodal natural killer/T-cell lymphoma,nasal type(NKTCL).We explored the efficacy and...
关键词：RADIOTHERAPY KILLER lymphoma 
Combination of gemcitabine,pegaspargase,etoposide,and dexamethasone(GPED)in treatment of advanced extranodal NK/T-cell lymphoma被引量：1
《Chinese Medical Journal》2023年第6期732-734,共3页Ruiying Fu Yuanzheng Liang Liqiang Wei Xindi Liu Yingshi Piao Liang Wang 
National Natural Science Foundation of China(No.82170181);Beijing Hospitals Authority Youth Programme(No.QML20200201);Beijing Natural Science Foundation(No.7222027);CSH Young Scholars and 3SBioPharmaceutical joint research project(No.KYC2201001)
To the Editor:Extranodal natural killer/T-cell lymphoma(ENKTCL)is a highly aggressive lymphoma,closely associated with Epstein–Barr virus(EBV)infection.By using the combination of radiotherapy(RT)and asparaginase-bas...
关键词：LYMPHOMA chemotherapy EPSTEIN 
全选清除导出
共9页<123456789>
检索报告 对象比较 聚类工具 使用帮助 返回顶部